This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Protokylol
- DrugBank Accession Number
- DB06814
- Background
Protokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Protokylol (DB06814)
- Weight
- Average: 331.368
Monoisotopic: 331.14197278 - Chemical Formula
- C18H21NO5
- Synonyms
- Protokylol
- Protokylolum
- Protoquilol
- External IDs
- AN 1031
- JB 251
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ABeta-2 adrenergic receptor agonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol The therapeutic efficacy of Acebutolol can be increased when used in combination with Protokylol. Acetazolamide The risk or severity of Cardiac Arrhythmia can be increased when Protokylol is combined with Acetazolamide. Acetyldigitoxin The risk or severity of Cardiac Arrhythmia can be increased when Protokylol is combined with Acetyldigitoxin. Aclidinium The risk or severity of Tachycardia can be increased when Protokylol is combined with Aclidinium. Acrivastine The therapeutic efficacy of Protokylol can be increased when used in combination with Acrivastine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Protokylol hydrochloride 7U7O8Q48IO 136-69-6 LOVXREQUMZKFCM-UHFFFAOYSA-N - International/Other Brands
- Asmetil / Caytine / Palison / Ventaire
Categories
- Drug Categories
- Adrenergic Agonists
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents to Treat Airway Disease
- Alcohols
- Amines
- Amino Alcohols
- Benzene Derivatives
- Biogenic Amines
- Biogenic Monoamines
- Catecholamines
- Catechols
- Dioxoles
- Epinephrine and similars
- Ethanolamines
- Long-acting beta-adrenoceptor agonists
- Phenols
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8Y5Y4EEO2V
- CAS number
- 136-70-9
- InChI Key
- LUMAEVHDZXIGEP-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H21NO5/c1-11(6-12-2-5-17-18(7-12)24-10-23-17)19-9-16(22)13-3-4-14(20)15(21)8-13/h2-5,7-8,11,16,19-22H,6,9-10H2,1H3
- IUPAC Name
- 4-(2-{[1-(2H-1,3-benzodioxol-5-yl)propan-2-yl]amino}-1-hydroxyethyl)benzene-1,2-diol
- SMILES
- CC(CC1=CC=C2OCOC2=C1)NCC(O)C1=CC=C(O)C(O)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 4798
- ChEBI
- 135413
- ChEMBL
- CHEMBL1201273
- Wikipedia
- Protokylol
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.236 mg/mL ALOGPS logP 1.29 ALOGPS logP 1.48 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 9.86 Chemaxon pKa (Strongest Basic) 8.98 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 91.18 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 88.78 m3·mol-1 Chemaxon Polarizability 35.44 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0409000000-bd175acedbe96fb225c3 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0059-0904000000-338e2075a48cceabe3c9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f89-0936000000-21703702e065c54bfce1 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0fai-0977000000-f827a56e4dc5e9a73349 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0f79-0952000000-d84819727c4b1b960bfb Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-0941000000-14269ac670120a959641 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 176.8725 predictedDeepCCS 1.0 (2019) [M+H]+ 179.23048 predictedDeepCCS 1.0 (2019) [M+Na]+ 186.37526 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
- Gene Name
- ADRB2
- Uniprot ID
- P07550
- Uniprot Name
- Beta-2 adrenergic receptor
- Molecular Weight
- 46458.32 Da
References
- Aggerbeck M, Guellaen G, Hanoune J: N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. Br J Pharmacol. 1979 Jan;65(1):155-9. [Article]
Drug created at September 14, 2010 16:21 / Updated at February 21, 2021 18:52